Black Diamond Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
BDTX$1.60-14.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Income Loss
(in thousands, except share and per share data)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| License revenue | $70,000 | $— |
| Operating expenses: | ||
| Research and development | $33,558 | $51,312 |
| General and administrative | 16,572 | 27,469 |
| Impairment of right-of-use assets and property and equipment | 7,348 | — |
| Total operating expenses | 57,478 | 78,781 |
| Income (loss) from operations | 12,522 | (78,781) |
| Other income (expense): | ||
| Interest income | 4,061 | 2,182 |
| Other income (expense) | 5,784 | 6,923 |
| Total other income (expense), net | 9,845 | 9,105 |
| Net income (loss) | $22,367 | $(69,676) |
| Net income (loss) per share - basic | $0.39 | $(1.27) |
| Net income (loss) per share - diluted | $0.39 | $(1.27) |
| Weighted average common shares outstanding - basic | 56,868,111 | 55,028,371 |
| Weighted average common shares outstanding - diluted | 57,562,746 | 55,028,371 |
| Comprehensive income (loss): | ||
| Net income (loss) | $22,367 | $(69,676) |
| Other comprehensive (loss) income: | ||
| Change in unrealized (loss) gain on investments, net | 77 | 51 |
| Comprehensive income (loss) | $22,444 | $(69,625) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.